Equitable Holdings Inc. Takes $860,000 Position in Edwards Lifesciences Corporation $EW

Equitable Holdings Inc. purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 9,507 shares of the medical research company’s stock, valued at approximately $860,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Jefferies Financial Group Inc. bought a new position in Edwards Lifesciences in the second quarter valued at about $3,584,000. Public Employees Retirement System of Ohio acquired a new position in Edwards Lifesciences during the second quarter worth about $16,823,000. MASTERINVEST Kapitalanlage GmbH bought a new position in shares of Edwards Lifesciences in the second quarter worth about $3,505,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,280,000. Finally, Proficio Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $262,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Bruls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,501 shares of company stock worth $408,213. 0.31% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EW shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Performance

NYSE EW opened at $90.19 on Friday. The company has a market capitalization of $51.93 billion, a price-to-earnings ratio of 51.83, a PEG ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a fifty day simple moving average of $89.54 and a 200 day simple moving average of $85.03.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the business earned $0.67 EPS. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.